165 related articles for article (PubMed ID: 30272645)
1. A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes.
Yang J; Wong LY; Tian XY; Wei R; Lai WH; Au KW; Luo Z; Ward C; Ho WI; Ibañez DP; Liu H; Bao X; Qin B; Huang Y; Esteban MA; Tse HF
J Vis Exp; 2018 Sep; (139):. PubMed ID: 30272645
[TBL] [Abstract][Full Text] [Related]
2. Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells.
Yang J; Wang Y; Zhou T; Wong LY; Tian XY; Hong X; Lai WH; Au KW; Wei R; Liu Y; Cheng LH; Liang G; Huang Z; Fan W; Zhao P; Wang X; Ibañez DP; Luo Z; Li Y; Zhong X; Chen S; Wang D; Li L; Lai L; Qin B; Bao X; Hutchins AP; Siu CW; Huang Y; Esteban MA; Tse HF
Stem Cell Reports; 2017 Mar; 8(3):605-618. PubMed ID: 28262545
[TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection.
Caron J; Pène V; Tolosa L; Villaret M; Luce E; Fourrier A; Heslan JM; Saheb S; Bruckert E; Gómez-Lechón MJ; Nguyen TH; Rosenberg AR; Weber A; Dubart-Kupperschmitt A
Stem Cell Res Ther; 2019 Jul; 10(1):221. PubMed ID: 31358055
[TBL] [Abstract][Full Text] [Related]
4. JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia.
Cayo MA; Cai J; DeLaForest A; Noto FK; Nagaoka M; Clark BS; Collery RF; Si-Tayeb K; Duncan SA
Hepatology; 2012 Dec; 56(6):2163-71. PubMed ID: 22653811
[TBL] [Abstract][Full Text] [Related]
5. New Approaches in Detection and Treatment of Familial Hypercholesterolemia.
Hartgers ML; Ray KK; Hovingh GK
Curr Cardiol Rep; 2015 Dec; 17(12):109. PubMed ID: 26482752
[TBL] [Abstract][Full Text] [Related]
6. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
[TBL] [Abstract][Full Text] [Related]
7. Induced pluripotent stem cell line ICGi037-A, obtained by reprogramming peripheral blood mononuclear cells from a patient with familial hypercholesterolemia due to heterozygous p.Trp443Arg mutations in LDLR.
Zakharova IS; Shevchenko AI; Tmoyan NA; Elisaphenko EA; Kalinin AP; Sleptcov AA; Nazarenko MS; Ezhov MV; Kukharchuk VV; Parfyonova YV; Zakian SM
Stem Cell Res; 2022 Apr; 60():102703. PubMed ID: 35152179
[TBL] [Abstract][Full Text] [Related]
8. Generation of two familial hypercholesterolemia patient-specific induced pluripotent stem cell lines harboring heterozygous mutations in the LDLR gene.
Gao J; Li J; Xu L; Yan CD; Knowles JW; Wu JC
Stem Cell Res; 2024 Aug; 78():103463. PubMed ID: 38852422
[TBL] [Abstract][Full Text] [Related]
9. DNA testing for familial hypercholesterolemia: improving disease recognition and patient care.
Vergopoulos A; Knoblauch H; Schuster H
Am J Pharmacogenomics; 2002; 2(4):253-62. PubMed ID: 12421096
[TBL] [Abstract][Full Text] [Related]
10. Restoration of Physiologically Responsive Low-Density Lipoprotein Receptor-Mediated Endocytosis in Genetically Deficient Induced Pluripotent Stem Cells.
Ramakrishnan VM; Yang JY; Tien KT; McKinley TR; Bocard BR; Maijub JG; Burchell PO; Williams SK; Morris ME; Hoying JB; Wade-Martins R; West FD; Boyd NL
Sci Rep; 2015 Aug; 5():13231. PubMed ID: 26307169
[TBL] [Abstract][Full Text] [Related]
11. iPSC-Derived Endothelial Cells Reveal LDLR Dysfunction and Dysregulated Gene Expression Profiles in Familial Hypercholesterolemia.
Zakharova IS; Shevchenko AI; Arssan MA; Sleptcov AA; Nazarenko MS; Zarubin AA; Zheltysheva NV; Shevchenko VA; Tmoyan NA; Saaya SB; Ezhov MV; Kukharchuk VV; Parfyonova YV; Zakian SM
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255763
[TBL] [Abstract][Full Text] [Related]
12. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
[TBL] [Abstract][Full Text] [Related]
13. A review of gene- and cell-based therapies for familial hypercholesterolemia.
Hajighasemi S; Mahdavi Gorabi A; Bianconi V; Pirro M; Banach M; Ahmadi Tafti H; Reiner Ž; Sahebkar A
Pharmacol Res; 2019 May; 143():119-132. PubMed ID: 30910740
[TBL] [Abstract][Full Text] [Related]
14. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
Jensen HK
Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.
Pek SLT; Dissanayake S; Fong JCW; Lin MX; Chan EZL; Tang JI; Lee CW; Ong HY; Sum CF; Lim SC; Tavintharan S
Atherosclerosis; 2018 Feb; 269():106-116. PubMed ID: 29353225
[TBL] [Abstract][Full Text] [Related]
16. Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.
Girona J; Rodríguez-Borjabad C; Ibarretxe D; Heras M; Amigo N; Feliu A; Masana L; Plana N;
J Clin Lipidol; 2018; 12(1):211-218. PubMed ID: 29102496
[TBL] [Abstract][Full Text] [Related]
17. DIAgnosis and Management Of familial hypercholesterolemia in a Nationwide Design (DIAMOND-FH): Prevalence in Switzerland, clinical characteristics and the diagnostic value of clinical scores.
Miserez AR; Martin FJ; Spirk D
Atherosclerosis; 2018 Oct; 277():282-288. PubMed ID: 30270060
[TBL] [Abstract][Full Text] [Related]
18. Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE.
Jarauta E; Pérez-Ruiz MR; Pérez-Calahorra S; Mateo-Gallego R; Cenarro A; Cofán M; Ros E; Civeira F; Tejedor MT
J Clin Lipidol; 2016; 10(6):1397-1405.e2. PubMed ID: 27919357
[TBL] [Abstract][Full Text] [Related]
19. Induced pluripotent stem cell line ICGi038-A, obtained by reprogramming peripheral blood mononuclear cells from a patient with familial hypercholesterolemia due to compound heterozygous c.1246C > T/c.940 + 3_940 + 6del mutations in LDLR.
Zakharova IS; Shevchenko AI; Tmoyan NA; Elisaphenko EA; Zubkova ES; Sleptcov AA; Nazarenko MS; Ezhov MV; Kukharchuk VV; Parfyonova YV; Zakian SM
Stem Cell Res; 2022 Apr; 60():102702. PubMed ID: 35152178
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
